Nanox (NNOX) Q2 2026 earnings review
Growth Narrative Collapses Amid $40.7M Write-Down and Cash Crunch
Nanox's Q2 2026 results represent a severe unwinding of the company's core growth narrative. While total revenue grew 37% YoY to $4.2M, the increase was entirely artificial—driven by the recent acquisition of Nanox Health IT. The core Nanox.ARC imaging business remains virtually non-existent, generating just $0.2M with 'no material change' in deployment levels. Far worse is the massive $40.7M impairment charge taken against the Nanox.AI segment, reducing its intangible value to a mere $1.9M. This write-down explicitly contradicts management's aggressive 2025 promises that the AI division would reach EBITDA breakeven in 2026. With cash depleting rapidly to $31.4M, the company has entered survival mode, slashing 67% of its Korean workforce and turning to dilutive equity raises.
🐂 Bull Case
The Korean facility shutdown and transition to outsourced manufacturing is complete, cutting 67% of the local workforce. This is expected to generate $2M in annual cost savings starting in 2027, slowing the cash burn.
The first Nanox Imaging Network (NIN) site is now live with patients scanning in Philadelphia. Ten U.S. distribution partners are secured, setting a foundation if the company can finally overcome deployment friction.
🐻 Bear Case
A $40.7M impairment charge on the AI business signals failure in a segment management previously highlighted as a primary driver. AI intangible value is now just $1.9M.
Nanox.ARC imaging and OEM revenue remains stuck at $0.2M. The company admitted there has been 'no material change' in deployed system numbers, rendering the hardware growth thesis dead in the water.
⚖️ Verdict: 🔴🔴
Strong Bear. The $40.7M AI impairment and admission of stagnant ARC deployments destroy the bull thesis. The company is surviving entirely on a legacy teleradiology business and recent IT acquisitions while rapidly burning through its remaining $31.4M in cash.
Key Themes
Massive AI Write-Down Contradicts Past Narrative
In Q3 2025, management aggressively sold investors on the promise that the Nanox.AI segment would achieve 'EBITDA breakeven on a quarterly basis during 2026.' This narrative has violently reversed. The company took a $40.7M impairment charge this quarter triggered by 'reduced forecasted revenues and operating results,' effectively writing off the segment's intangible value down to $1.9M. This signals a complete collapse of AI as an internal growth engine.
Nanox.ARC Deployments Hit a Brick Wall
The company's core technology, the Nanox.ARC multi-source system, is failing to gain commercial traction. Despite boasting about 'hundreds' of pipeline agreements in 2025, Q2 2026 hardware revenue printed a miserable $0.2M. More alarmingly, the PR explicitly states there has been 'no material change in the number of Nanox.ARC systems in various stages of deployment.' The transition from signed contracts to actively billing clinics remains utterly broken.
Critical Liquidity Crunch and Dilution
Cash burn is accelerating into a crisis. The company ended Q2 with just $31.4M in cash and equivalents, down sharply from $60.0M at the end of 2025. With a quarterly adjusted EBITDA loss of $11.3M, the runway is functionally less than nine months. Consequently, management was forced to raise $8.5M via a highly dilutive registered direct offering immediately post-quarter, warning that they 'intend to continue raising funds.'
Nanox Health IT Acquisition Masking Decline
The only bright spot in the top line was the 'AI and Software' segment growing to $1.0M. However, this is artificial growth: $0.9M of this came directly from the consolidation of the recently acquired Nanox Health IT (formerly Vaso Healthcare IT). Stripping this out, the core company revenue actually shrank sequentially. This acquisition is currently the sole driver keeping the top line from collapsing.
Slashing Structural Costs to Survive
Management's 'multi-pronged cost reduction initiative' is in full swing, most notably through the gutting of South Korea operations. Moving entirely to third-party manufacturing partners has resulted in a 67% workforce reduction in the region. This restructuring will cost $0.9M upfront but is expected to generate $2M in annual savings starting in 2027. Nanox is no longer optimizing for growth; it is optimizing for survival.
Mounting Legal and Geopolitical Risks
A new class action lawsuit (Steele v. Nano-X Imaging Ltd.) filed in June 2026 alleges securities fraud regarding disclosures around the Korean manufacturing facility. This creates an expensive legal distraction precisely when cash is scarce. Furthermore, the company highlighted ongoing geopolitical instability in Israel as a macroeconomic risk that could further strain its Petach Tikva-based operations and supply chain continuity.
Other KPIs
Reversing violently from -107% in Q2 2025. While heavily distorted by the $40.7M intangible impairment charge running through the cost of revenues, even the Non-GAAP Gross Loss Margin remains structurally negative at -13%. The company continues to lose money on every incremental dollar of sales.
Stable. The legacy business remains the primary cash generator but shows absolutely zero growth, printing $3.0M (flat YoY from $3.0M, and slightly down from $3.1M in prior quarters). It is a reliable floor, but not a growth engine.
Guidance
The company conspicuously offered zero forward-looking financial guidance in this release. Following the quiet withdrawal of their ambitious '$35 million in 2026' target in Q1 due to 'deployment variability,' management is now relying strictly on qualitative updates ('disciplined execution') rather than hard numbers.
Key Questions
The Nanox.ARC Deployment Bottleneck
You noted 'no material change' in ARC deployments this quarter despite 10 U.S. distribution partners. Is the bottleneck technical failure, lack of customer demand, or regulatory friction at the state level?
Future of Nanox.AI
Following a catastrophic $40.7M impairment that wiped out the vast majority of the AI segment's intangible value, does the company plan to divest or shut down the internal AI R&D entirely to save cash?
Capital Requirements and Dilution
With an adjusted EBITDA burn rate of roughly $11 million per quarter and just $31 million in cash, the $8.5M recent raise buys less than three months. Exactly how much capital do you need to raise over the next 12 months, and at what valuation are you willing to issue equity?